Unknown

Dataset Information

0

A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.

ABSTRACT: Myotonic dystrophy type 1 (DM1) is caused by an expanded CUG repeat (CUG(exp)) that sequesters muscleblind-like 1 protein (MBNL1), a protein that regulates alternative splicing. CUG(exp) RNA is a validated drug target for this currently untreatable disease. Herein, we develop a bioactive small molecule (1) that targets CUG(exp) RNA and is able to inhibit the CUG(exp)·MBNL1 interaction in cells that model DM1. The core of this small molecule is based on ligand 2, which was previously reported to be active in an in vitro assay. A polyamine-derivative side chain was conjugated to this core to make it aqueous-soluble and cell-penetrable. In a DM1 cell model this conjugate was found to disperse CUG(exp) ribonuclear foci, release MBNL1, and partially reverse the mis-splicing of the insulin receptor pre-mRNA. Direct evidence for ribonuclear foci dispersion by this ligand was obtained in a live DM1 cell model using time-lapse confocal microscopy.

SUBMITTER: Jahromi AH 

PROVIDER: S-EPMC3683132 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.

Jahromi Amin Haghighat AH   Nguyen Lien L   Fu Yuan Y   Miller Kali A KA   Baranger Anne M AM   Zimmerman Steven C SC  

ACS chemical biology 20130320 5

Myotonic dystrophy type 1 (DM1) is caused by an expanded CUG repeat (CUG(exp)) that sequesters muscleblind-like 1 protein (MBNL1), a protein that regulates alternative splicing. CUG(exp) RNA is a validated drug target for this currently untreatable disease. Herein, we develop a bioactive small molecule (1) that targets CUG(exp) RNA and is able to inhibit the CUG(exp)·MBNL1 interaction in cells that model DM1. The core of this small molecule is based on ligand 2, which was previously reported to  ...[more]

Similar Datasets

Unknown Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.
| S-EPMC4850456 | biostudies-literature
Unknown Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2).
| S-EPMC3203617 | biostudies-literature
Unknown Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy.
| S-EPMC5963859 | biostudies-literature
Unknown Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1.
| S-EPMC8634727 | biostudies-literature
Unknown Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
| S-EPMC5016119 | biostudies-other
Unknown rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.
| S-EPMC5964235 | biostudies-literature
Unknown Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1).
| S-EPMC2645920 | biostudies-literature
Unknown Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy.
| S-EPMC7452101 | biostudies-literature
Unknown Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.
| S-EPMC3925341 | biostudies-literature
Unknown Computational investigation of RNA CUG repeats responsible for myotonic dystrophy 1.
| S-EPMC4606397 | biostudies-literature